Management of post-transplant lymphoproliferative disorders

被引：2

作者：

Dierickx, Daan ^{[1
]}

Vergote, Vibeke ^{[1
]}

机构：

[1] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium

来源：

HEMASPHERE | 2019年 / 3卷

关键词：

RECIPIENTS; INFUSIONS; PROGNOSIS;

D O I：

10.1097/HS9.0000000000000226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Take home messages Reduction of immune suppression followed by rituximab has become the standard of care in the majority of post-transplant lymphoproliferative disorders. Currently pre-emptive therapy is only justified in allogeneic hematopoietic stem cell recipients. Adoptive immunotherapy is a very promising therapeutic modality, both in pre-emptive setting and as treatment of established Epstein-Barr virus-positive post-transplant lymphoproliferative disorder. However, use is still restricted because of labor-intensive procedure, reimbursement issues, and availability problems.

引用

页码：74 / 77

页数：4

共 20 条

[1]

[Anonymous], 2017, WHO CALSSIFICATION T

[2]

Bollard CM, 2016, BLOOD, V127, P1123

[3] Post-transplant lymphoproliferative disorders [J].

Dharnidharka, Vikas R. ;

Webster, Angela C. ;

Martinez, Olivia M. ;

Preiksaitis, Jutta K. ;

Leblond, Veronique ;

Choquet, Sylvain .

NATURE REVIEWS DISEASE PRIMERS, 2016, 2

[4] Post-Transplantation Lymphoproliferative Disorders in Adults [J].

Dierickx, Daan ;

Habermann, Thomas M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (06) :549-562

[5] How I treat posttransplant lymphoproliferative disorders [J].

Dierickx, Daan ;

Tousseyn, Thomas ;

Gheysens, Olivier .

BLOOD, 2015, 126 (20) :2274-2283

[6] Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy [J].

Granato, Marisa ;

Romeo, Maria Anele ;

Tiano, Mariangela Sara ;

Santarelli, Roberta ;

Gonnella, Roberta ;

Gilardini Montani, Maria Saveria ;

Faggioni, Alberto ;

Cirone, Mara .

SCIENTIFIC REPORTS, 2017, 7

[7] Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients [J].

Heslop, Helen E. ;

Slobod, Karen S. ;

Pule, Martin A. ;

Hale, Gregory A. ;

Rousseau, Alexandra ;

Smith, Colton A. ;

Bollard, Catherine M. ;

Liu, Hao ;

Wu, Meng-Fen ;

Rochester, Richard J. ;

Amrolia, Persis J. ;

Hurwitz, Julia L. ;

Brenner, Malcolm K. ;

Rooney, Cliona M. .

BLOOD, 2010, 115 (05) :925-935

[8] Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation [J].

Jiang, Xinmiao ;

Xu, Lanping ;

Zhang, Yu ;

Huang, Fen ;

Liu, Daihong ;

Sun, Jin ;

Song, Chaoyang ;

Liang, Xinquan ;

Fan, Zhiping ;

Zhou, Hongsheng ;

Dai, Min ;

Liu, Can ;

Jiang, Qianli ;

Xu, Na ;

Xuan, Li ;

Wu, Meiqing ;

Huang, Xiaojun ;

Liu, Qifa .

ONCOIMMUNOLOGY, 2016, 5 (05)

[9] Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression [J].

Jones, Richard J. ;

Lempridee, Tawin ;

Wang, Xiaobin ;

Lee, Hans C. ;

Mertz, Janet E. ;

Kenney, Shannon C. ;

Lin, Heather C. ;

Baladandayuthapani, Veerabhadran ;

Dawson, Christopher W. ;

Shah, Jatin J. ;

Weber, Donna M. ;

Orlowski, Robert Z. .

CLINICAL CANCER RESEARCH, 2016, 22 (19) :4901-4912

[10] Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation [J].

Kinch, Amelie ;

Sundstrom, Christer ;

Baecklund, Eva ;

Backlin, Carin ;

Molin, Daniel ;

Enblad, Gunilla .

LEUKEMIA & LYMPHOMA, 2019, 60 (02) :376-384

← 1 2 →